Industry News

- Read more about Natco Pharma settled patent infringement with Gilead Sciences & others
Natco Pharma and Alvogen have settled the patent infringement suit filed by Gilead Sciences, Hoffmann-La Roche, F. Hoffmann-La Roche Ltd. and Genentech Inc. against them in New Jersey District Court.
- Read more about 300 million child-friendly antimalarial treatments supplied without profit by Novartis
- Coartem® Dispersible*, the first WHO prequalified pediatric antimalarial treatment, has become the standard of care in over 30 malaria-endemic countries
- Since 2009, Novartis has supplied 300 million Coartem® Dispersible treatments without profit, mostly to the public sector, to treat children suffering from malaria
- Together with other innovations, Coartem® Dispersible contributed to reduce the malaria death rate by 71% for children under the age of 5 years
- Read more about Rhizen Pharmaceuticals entered license agreement with Novartis
Rhizen Pharmaceuticals have entered into an exclusive, worldwide license agreement, with Novartis for the development and commercialization of Rhizen’s, inhaled dual PI3K - delta gamma inhibitor and its closely related compounds for various indications.
- Read more about Sun Pharma collaborate for research with Israel & Spain
Sun Pharma entered into a tripartite research and option agreement with Israel-based Weizmann Institute of Science and Spain’s Health Research Institute of Santiago de Compostela (IDIS) to develop breakthrough products for the treatment of neurological diseases like brain stroke; as well as glioblastoma, a lethal brain cancer.
- Read more about FDA Advisory Committee Recommends Approval of Teva’s Asthma Biologic Reslizumab
Teva Pharmaceutical Industries Ltd announced that the U.S. Food and Drug Administration’s (FDA) Pulmonary-Allergy Drugs Advisory Committee recommended approval of reslizumab, a humanized anti-interleukin-5 (IL-5) IgG4K monoclonal antibody (mAb), in adult patients aged 18 years and older. Reslizumab is a targeted biologic therapy for the treatment of inadequately controlled asthma in patients with elevated blood eosinophils, despite an inhaled corticosteroid (ICS)-based treatment regimen.
- Read more about FDA allows marketing of cooling cap to reduce hair loss during chemotherapy
U.S. Food and Drug Administration cleared for marketing in the United States the first cooling cap to reduce hair loss in female breast cancer patients undergoing chemotherapy.
- Read more about Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA Combination Trial
Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly’s cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck’s KEYTRUDA® (pembrolizumab) in a Phase I study across multiple tumor types. Based on the Phase I trial results, the collaboration has the potential to progress to Phase II trials in patients who have been diagnosed with either metastatic breast cancer or non-small cell lung cancer (NSCLC).
- Read more about Sanofi: Dengvaxia®, World's First Dengue Vaccine, Approved in Mexico
Sanofi Pasteur, the vaccines division of Sanofi, announced that the Mexican authorities have granted marketing authorization to Dengvaxia®, making it the first vaccine to be licensed in the world for the prevention of dengue.
- Read more about Malnutrition in India is Declining Faster than before, but not Fast Enough to Meet Global Targets
-Two new reports say urgent action needed to build on new momentum

-The benefit cost ratio of investing in the scaling up nutrition programmes in India is 34 to 1

-India’s stunting “represents the largest loss of human potential in any country in human history
- Read more about NeoBiocon Partners with Novartis to Offer Vildagliptin for Diabetics in UAE
(BWI); NeoBiocon, a collaboration between Asia’s leading biopharmaceuticals company Biocon Ltd and Dr. B.R. Shetty, Chairman of the UAE-based Neopharma, announced today that it has partnered with Novartis Middle East FZE, to market Jalra (Vildagliptin) and Jalra-M (Vildagliptin + Metformin) in UAE. This partnership will help NeoBiocon expand its product offerings in the metabolics segment and will immensely benefit diabetics in UAE.